[Skip to content]

European Parkinson's Disease Association
Search our Site
Next issue
Previous Issue

EPNN Journal Issue 12 - Spring 2008

EPNN Journal issue 12
Click on image to download


  • EU Directive on Electromagnetic Fields to Protect MRI
    The European Parliament has approved the European Commission’s request to postpone the European Union’s Directive 2004/40/EC, which sets limits on occupational exposure to electromagnetic fields. Adopted by the European Parliament and Council in April 2004, this legislation was due to enter into force in April 2008.
  • Gene Therapy – Tracking the Changes

    Positron emission tomography (PET) scans tracking changes in 12 people with Parkinson’s who received experimental gene therapy show that the treatment normalises brain function and the effects are still present a year later.

  • People with RLS at Risk of Stroke and Heart Disease

    The risk of stroke and heart disease is greatest in people who have the most frequent and severe symptoms of restless legs syndrome (RLS), according to Harvard Medical School (US) research, published in Neurology in January.

  • EBC Forum – Promoting Research Roadmap

    The European Brain Council (EBC) – a co-ordinating body formed by European organisations in neurology, neurosurgery, psychiatry, neuroscience, patient groups and industry – is developing a series of annual multidisciplinary forums.

  • Tackling Low Health Literacy

    Studies have shown that people who have limited health literacy are 12-18 times more likely to be unable to identify their own medications and distinguish them from one another, than people with greater health literacy.

  • 1000 Genomes Project Launched

    The 1000 Genomes Project – an ambitious three-year initiative involving the sequencing of the genomes (entire DNA content) of at least 1,000 people to create the most detailed picture of human genetic variation to date – was launched in January.

  • Positive Results for FIRST-STEP

    The Orion Corporation has been informed by its marketing partner, Novartis, of the positive outcome of the Phase III FIRST-STEP clinical study conducted in 423 people with early Parkinson’s disease.

  • Chemical Trigger Identified

    Researchers at the Saint Louis University School of Medicine have identified a key brain chemical, known as DOPAL, which causes Parkinson’s. Their findings were published in an early online edition of Acta Neuropathologica in October.

  • Forty Years On

    UK neurologist Leslie Findley provides an update on drug treatments currently available.

    Italian neurologist Fabrizio Stocchi talks about the latest thinking in relation to levodopa treatment.

  • Parkinson’s Medication at a Glance

    Jackie Russell discusses the advantages of exercise for people with Parkinson’s.

  • Dancing and its Benefits

    Olie Westheimer from the US describes the innovative dance and movement classes she has developed.

  • Living the Dream

    Bridget McCall provides a checklist for those considering retiring abroad.

  • Quivers and Quavers

    Bridget McCall describes an exciting voice therapy initiative.

  • Putting Genetics into Perspective

    Italians Enza Maria Valente and Anna Rita Bentivoglio highlight some of the latest developments in genetics.